From: High rate of bleeding and arterial thrombosis in COVID-19: Saudi multicenter study
Age | ICU | Site of bleeding | Severity | Anticoagulant at time of bleeding |
---|---|---|---|---|
45 | Yes | Lung | Major | UFH 5000Â IU TID |
62 | Yes | Lower GI | Major | Enoxaparin 40Â mg once |
62 | Yes | Hematuria | Non major | Aspirin |
61 | Yes | Cutaneous | Non major | UFH 5000Â IU TID |
73 | Yes | CNS | Major | Enoxaparin 40Â mg once |
64 | Yes | Cutaneous | Non major | Enoxaparin 40Â mg once |
59 | Yes | Cutaneous | Non major | Enoxaparin 40Â mg once |
62 | No | Musculoskeletal | Major | Enoxaparin 40Â mg once |
31 | Yes | CNS | Major | Enoxaparin 40Â mg once |
74 | Yes | Cutaneous | Non major | Enoxaparin 40Â mg BID |
41 | Yes | Lower GI | Non major | Full dose UFH |